脑微出血与强化降压对血肿扩大及功能结局的影响:ATACH-2随机临床试验的二次分析
该研究为ATACH-2试验的预设亚组分析,纳入167例急性脑出血患者,其中120例存在脑微出血。分析显示,无论有无脑微出血,强化降压与标准降压在3个月不良结局(改良Rankin量表评分4-6分)和血肿扩大风险上均无显著交互作用。结论认为脑微出血在脑出血患者中高度流行,但似乎不影响对急性强化降压治疗的反应。
要点
- 在急性脑出血患者中,脑微出血的发生率为120/167例。
- 有脑微出血者强化与标准降压的不良结局风险相似(相对风险1.19,95%CI 0.61-2.33,P=0.61)。
- 无脑微出血者不良结局风险也相似,且治疗与脑微出血无显著交互作用。
核心结论
- 脑微出血在脑出血患者中高度流行,但似乎不影响对急性强化降压治疗的反应。
研究设计与样本
- ATACH-2试验的预设亚组分析,采用意向性治疗范式。
- ATACH-2为开放标签国际随机临床试验,纳入1000例急性脑出血患者。
- 参与者于2011年5月至2015年9月入组,随访3个月。
- 纳入标准为年龄至少18岁、CT示血肿体积小于60 mL、初始评估格拉斯哥昏迷量表评分至少5分、症状发作4.5小时内可启动研究药物。
- 833例被排除,最终167例具有可解读的轴位T2*加权梯度回波磁共振序列以评估脑微出血的患者纳入本亚组分析。
主要发现
- 共纳入167例患者,平均(标准差)年龄61.9(13.2)岁,98例(58.7%)为男性。
- 120例患者存在脑微出血。
- 46/157例(29.3%)患者结局不良(改良Rankin量表评分≥4分),29/144例(20.1%)患者观察到血肿扩大。
- 有脑微出血者中,强化与标准急性降压组的不良结局风险相似(相对风险1.19;95%CI 0.61-2.33;P=0.61)。
- 无脑微出血者中,强化与标准急性降压组的不良结局风险也相似(相对风险1.42;95%CI 0.43-4.70;P=0.57),未观察到显著交互作用(交互系数0.18;95%CI -1.20至1.55;P=0.80)。
关键数值与推荐
- 主要结局为3个月死亡或残疾(改良Rankin量表评分4-6分)。
- 次要结局为随机化后24小时CT扫描较入组扫描血肿体积扩大至少33%。
- 有脑微出血者强化与标准降压的不良结局相对风险1.19(95%CI 0.61-2.33;P=0.61)。
- 无脑微出血者强化与标准降压的不良结局相对风险1.42(95%CI 0.43-4.70;P=0.57)。
- 治疗与脑微出血对不良结局的交互系数0.18(95%CI -1.20至1.55;P=0.80),对血肿扩大的交互系数0.62(95%CI -1.08至2.31;P=0.48)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Response to intensive blood pressure (BP) lowering in acute intracerebral hemorrhage (ICH) might vary with the degree of underlying cerebral small vessel disease. OBJECTIVES: To characterize cerebral microbleeds (CMBs) in acute ICH and to assess the potential for interaction between underlying small vessel disease (as indicated by CMB number and location) and assignment to acute intensive BP targeting for functional outcomes and hematoma expansion. DESIGN, SETTING, AND PARTICIPANTS: Preplanned subgroup analyses in the Antihypertensive Treatment of Acute Cerebral Hemorrhage 2 (ATACH-2) trial were performed. The ATACH-2 was an open-label international randomized clinical trial that investigated optimal acute BP lowering in 1000 patients with acute ICH. Analyses followed the intent-to-treat paradigm. Participants were enrolled between May 2011 and September 2015 and followed up for 3 months. Eligible participants were aged at least 18 years with ICH volumes less than 60 mL on computed tomography (CT) and a Glasgow Coma Scale score of at least 5 on initial assessment, in whom study drug could be initiated within 4.5 hours of symptom onset. Eight hundred thirty-three participants were excluded, leaving 167 who had an interpretable axial T2*-weighted gradient-recalled echo sequence on magnetic resonance imaging to assess CMBs for inclusion in these subgroup analyses. MAIN OUTCOMES AND MEASURES: The primary outcome of interest was death or disability (modified Ranking Scale score, 4-6) at 3 months. The secondary outcome of interest was hematoma volume expansion of at least 33% on a CT scan obtained 24 hours after randomization compared with the entry scan. RESULTS: A total of 167 patients were included; their mean (SD) age was 61.9 (13.2) years, and 98 (58.7%) were male. Cerebral microbleeds were present in 120 patients. Forty-six of 157 (29.3%) patients had poor outcome (modified Ranking Scale score, ≥4), and hematoma expansion was observed in 29 of 144 (20.1%) patients. Risk of poor outcome was similar for those assigned to intensive vs standard acute BP lowering among patients with CMBs (relative risk, 1.19; 95% CI, 0.61-2.33; P = .61) and those without CMBs (relative risk, 1.42; 95% CI, 0.43-4.70; P = .57), and no significant interaction was observed (interaction coefficient, 0.18; 95% CI, -1.20 to 1.55; P = .80). Risk of hematoma expansion was also similar, and no significant interaction between treatment and CMBs was observed (interaction coefficient, 0.62; 95% CI, -1.08 to 2.31; P = .48). CONCLUSIONS AND RELEVANCE: Cerebral microbleeds are highly prevalent among patients with ICH but do not seem to influence response to acute intensive BP treatment. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01176565.
引用
- Shoamanesh A, Morotti A, Romero JM, et al. Cerebral Microbleeds and the Effect of Intensive Blood Pressure Reduction on Hematoma Expansion and Functional Outcomes: A Secondary Analysis of the ATACH-2 Randomized Clinical Trial. JAMA Neurol. 2018. PMID: 29710119. doi:10.1001/jamaneurol.2018.0454
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。